


Foundations of Cardiometabolic Health Certification Course

Certified
Cardiometabolic
Health Professional
(CCHP)



**Epidemiology of Atrial Fibrillation:
Modifiable Risk Factors and
Concept of Atrial Fibrillation as a Systemic
Illness**

Usha B. Tedrow, MD MSc

**Associate Professor, Harvard Medical School
Fellowship Director, Clinical Cardiac
Electrophysiology Program**

The Most Prevalent Arrhythmia: Atrial Fibrillation





Figure 2. World map showing the age-adjusted prevalence rates (per 100,000 population) of atrial fibrillation in the 21 Global Burden of Disease regions, 2010.

33.5 Million Worldwide have AF
(Screening?, Risk Factors? Life Expectancy? Genetics?)

Projected Prevalence of Atrial Fibrillation (AF) (United States)


- An estimated 3-7 million people are diagnosed with AF
- This number is expected to rise to 5.6-12.1 million by 2050 in most conservative estimates



If rate of increase in incidence does not change

Go, ATRIA Study estimates


Atrial Fibrillation Incidence Rates by Age



Atrial Fibrillation Incidence: Age and Sex Differences

Framingham Heart Study

- AF risk doubles for each advancing decade of life.
- Men have an adjusted 1.5 times risk of AF greater than women.



Foundations of Cardiometabolic Health Certification Course

Certified
Cardiometabolic
Health Professional
(CCHP)




AF: Causes & Classification


Usha B. Tedrow, MD MSc

Associate Professor, Harvard Medical School
Fellowship Director, Clinical Cardiac
Electrophysiology Program

What Causes AF?




CENTRAL ILLUSTRATION: Incidence, Predictors, and Outcomes of Atrial Arrhythmias in Patients Admitted With COVID-19 Versus Influenza




Risk Factors for New AF/AFL in COVID-19_{Primary}

- ↑ Inflammatory markers
- ↑ Myocardial injury
- ↑ Intubation and vasopressor requirement
- ↑ Use of steroids



Types of AF


Paroxysmal AF



Triggers result in AF that starts and stops by itself




Persistent AF



Progression to longer episodes, days to weeks




Permanent AF




Fibrosis has progressed to the point where AF is continually present


Pulmonary Vein Triggers





Myocardial sleeve around PV





Initiation of AF
by rapid firing
in a PV



Pulmonary Vein Isolation with Substrate Modification






MRI Fibrosis and Histology in 84 yo F with AF and Severe MR



Range of Atrial Fibrosis: Related to AF Severity?

Not all AF Patients are equal



Foundations of Cardiometabolic Health Certification Course

Certified Cardiometabolic Health Professional (CCHP)




Risk Factors for AF

Usha B. Tedrow, MD MSc

Associate Professor, Harvard Medical School
Fellowship Director, Clinical Cardiac
Electrophysiology Program

Modifiable Factors that Influence AF Risk


- Blood Pressure
- Weight
- Moderate Exercise
- Moderation of Alcohol
- Avoid Smoking
- Diabetes
- Sleep Apnea



50-60% reductions in AF Risk associated with optimal AF risk factors

Systolic Blood Pressure and Risk of AF Among Apparently Healthy Women

Age-Adjusted AF Incidence by Baseline SBP:




Updated BP Measurements:

Systolic BP	120-129	130-139	140-159	≥160 mmHg
	n=9,448	n=6,952	n=5,304	n=444
Incident AF	136	160	181	27
Multivariable	1.14 (0.89-1.46)	1.37 (1.07-1.76)	1.71 (1.33-2.21)	2.21 (1.45-3.36)
Combined with DBP	1.18 (0.91-1.51)	1.43 (1.09-1.87)	1.78 (1.34-2.38)	2.29 (1.45-3.63)

Atrial Fibrillation and Obesity

Framingham Heart Study


Men



Number at risk

Normal	755	699	614	557	482
Overweight	1216	1146	1023	908	776
Obese	413	380	336	280	238

Women




1536	1479	1394	1282	1180
898	852	776	696	612
464	444	397	345	299

Obesity versus normal BMI: HR 1.5 (adjusted risk)

Mediated by left atrial enlargement

Dynamic BMI and Atrial Fibrillation Risk in WHS

Age adjusted AF Incidence by Baseline WHO Categories of BMI:



Updated BMI Measurements:

BMI	<25 kg/m ²	25-30 kg/m ²	≥ 30kg/m ²	Continuous
N (%)	17415 (51.1%)	10580 (30.8%)	6185 (18.0%)	N=34,309
Incident AF	344	259	231	834
Age-adjusted	Referent	1.28 (1.09, 1.53)	1.98 (1.67, 2.36)	1.06 (1.05, 1.07)
Multivariable	Referent	1.22 (1.02, 1.45)	1.65 (1.36, 2.00)	1.04 (1.03-1.06)

BMI and AF: Meta-Analysis

Observational Estimates from 7 Prospective Cohorts


51 646 individuals, 4178 AF Cases

	Age, Sex Adjusted (HR, 95% CI)	+ Confounders (HR, 95% CI)	+ Mediators (HR, 95% CI)	+ Height (HR, 95% CI)
Per 1 kg/m² ↑ BMI				
AGES	1.03 (1.01-1.05)	1.03 (1.01-1.06)	1.03 (1.01-1.05)	1.03 (1.01-1.05)
ARIC	1.06 (1.05-1.07)	1.07 (1.06-1.08)	1.05 (1.03-1.06)	1.05 (1.04-1.06)
FHS	1.05 (1.03-1.06)	1.05 (1.03-1.07)	1.04 (1.02-1.06)	1.04 (1.02-1.06)
PREVEND	1.06 (1.01-1.10)	1.05 (1.01-1.10)	1.05 (1.00-1.11)	1.06 (1.00-1.12)
RS-I	1.05 (1.03-1.07)	1.04 (1.02-1.07)	1.03 (1.00-1.05)	1.04 (1.01-1.06)
RS-II	1.05 (1.00-1.11)	1.05 (1.00-1.11)	1.03 (0.97-1.11)	1.03 (0.97-1.10)
WGHS	1.05 (1.04-1.06)	1.05 (1.04-1.06)	1.03 (1.02-1.05)	1.04 (1.03-1.05)
Meta-Analysis				
Observational estimate	1.05 (1.04-1.06)	1.05 (1.04-1.06)	1.04 (1.03-1.05)	1.04 (1.03-1.05)
Test for overall effect	p<0.001	p<0.001	p<0.001	p<0.001
Heterogeneity [I ² , Qp]	[24%, 0.37]	[47.5%, 0.10]	[5.1%, 0.68]	[0%, 0.78]


Multivariable adjustment included confounders (smoking, EtOH) and mediators (systolic and diastolic blood pressure, diabetes mellitus, history of coronary heart disease, history of heart failure)

Each 1 kg/m² ↑ observed BMI associated with 4% ↑ risk of incident AF

Goal-Directed Weight Management in AF




Time (Days)	0	365	730	1095	1460	1825
≥ 10 WL	135	101	72	42	31	18
3-9% WL	103	62	36	22	13	7
<3% WL or gain	117	66	44	22	11	9



Time (Days)	0	365	730	1095	1460	1825
≥ 10 WL	135	130	114	86	67	36
3-9% WL	103	93	83	57	35	22
<3% WL or gain	117	105	85	53	32	22

Goal-Directed Weight Management in AF




Weight loss $\geq 10\%$ resulted in a 6-fold ($p < 0.001$) increased arrhythmia-free survival compared with the other 2 groups

A separate analysis of the same pts showed: Arrhythmia-free survival was greatest in those who gained “fitness,” a gain of ≥ 2 METs compared to those with smaller gains in cardiorespiratory fitness ($p < 0.001$)



Time (Days)	0	303	730	1053	1400	1823
≥ 10 WL	135	101	72	42	31	18
3-9% WL	103	62	36	22	13	7
<3% WL or gain	117	66	44	22	11	9

Time (Days)	0	303	730	1053	1400	1823
≥ 2 METs	135	130	114	86	67	36
<2 METs	103	93	83	57	35	22
Gain in fitness	117	105	85	53	32	22

Proposed Mechanism of Weight Loss and AF Reduction




Particularly Important Because Catheter Ablation is Less Effective and More Risky in Obese Patients



Sleep Apnea

- Obstructive sleep apnea (OSA) markedly increases the risk of both AF and stroke
- OSA pts are 5 times more likely to develop AF than those without sleep apnea
- Risk of AF is directly correlated with the severity of sleep apnea
- Mechanisms:
 - Autonomic: OSA stimulates excess vagal tone, while triggering activation of the sympathetic nervous system (Worsening of underlying hypertension)
 - Structural/hemodynamic: Upper airway obstruction during inhalation → negative intrathoracic pressure, increasing atrial blood volume → Left atrial enlargement

AF Recurrence in Users vs nonusers of CPAP in 2 groups of patients with OSA: PVI and Non-PVI groups




The forest plot exhibits effect size of each included study (**solid box**) with 95% confidence interval (CI) (**black lines through solid squares**). The **diamond (and broken vertical line)** at the bottom represents pooled summary estimate with its CI given by its width. AF = atrial fibrillation; CPAP = continuous positive airway pressure; OSA = obstructive sleep apnea; RR = relative risk ratio.

Type 2 Diabetes and AF, SGLT-2 Inhibitors

Patients with DM2 have a 35% higher risk of AF compared with age- and gender-matched control subjects

SGLT-2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.

SGLT-2 inhibitor use can reduce AF risk by **19%**



Frequency of Jogging and Atrial Fibrillation

Physicians' Health Study


Frequency of Habitual Jogging	<1/Wk	1-2/Wk	3-4/Wk	5-7/Wk	P-Trend
Model 1*– Hazard Ratio	0.78	0.90	1.16	1.42	0.013
Multivariable Model 2†	0.91	1.03	1.30	1.53	<0.001
Multivariable Model 3‡	0.83	0.91	1.22	1.45	<0.01

* Model 1: age and treatment assignment.

† Model 2: age, treatment assignment, parental history of premature MI, alcohol, smoking, fish consumption, multivitamin, vitamin C and vitamin E intake, **BMI, DM, HTN, Hyperlipidemia, LVH, CHF, and CVD.**

‡ Model 3: age, treatment assignment, parental history of premature MI, alcohol, smoking, fish consumption, multivitamin, and vitamin C and vitamin E intake.


Meta-Analysis of AF Risk in Athletes Compared with Controls



AF Risk Factors Specific to Women

Women's Health Initiative
10,739 Women with Prior Hysterectomy


Women randomized to Estrogen had 17% more AF



Women's Health Study
30,034 Women without TAH-BSO

Hazard Ratio for AF in Women on Estrogen Alone:
1.22 (P=0.035)

*No Increased Risk associated Menopause
beyond that associated with Age*



Foundations of Cardiometabolic Health Certification Course

Certified Cardiometabolic Health Professional (CCHP)




Dietary Targets

Usha B. Tedrow, MD MSc

Associate Professor, Harvard Medical School
Fellowship Director, Clinical Cardiac
Electrophysiology Program

Risk of AF by Weekly Alcohol Consumption in Men


Copenhagen City Heart Study



Heavy alcohol consumption in men associated with higher adjusted AF risk unexplained by CHD or BP
Risk not observed in women, but few drank heavily.


Alcohol Intake and Risk of AF

Meta-analysis of Prospective Studies



CENTRAL ILLUSTRATION Forest Plot of Relative Risks of Atrial Fibrillation Per 1 Drink/Day Increment in Alcohol Consumption

Alcohol Intake and Atrial Fibrosis



Alcohol Abstinence for ATRIAL FIBRILLATION

OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL

140

Adults with atrial fibrillation and regular
Alcohol consumption ≥ 10 standard drinks
per week

Abstinence (N=70)

No alcohol for 6
months

Control (N=70)

Continue consuming
their usual amount of
alcohol

Atrial fibrillation recurrence

53%

73%

HR, 0.55; 95% CI, 0.36-0.84; P= 0.005

**Median percentage of time in atrial
fibrillation during 6 months follow-up**

0.5%

1.2%

Caffeine Intake and AF Risk in Women in WHS

	Quintile of Caffeine Intake					
	1	2	3	4	5	P, Linear
Number of events	203	172	184	208	178	
Age-adjusted incidence rate	2.15	1.89	2.01	2.24	2.04	
Age-adjusted relative risk	Referent	0.89 (0.74-1.08)	0.97 (0.77-1.22)	0.97 (0.81-1.18)	0.90 (0.73-1.10)	0.44
Multivariable* relative risk	Referent	0.88 (0.72-1.06)	0.78 (0.64-0.95)	0.96 (0.79-1.16)	0.89 (0.73-1.09)	0.45

* Adjusted for age, systolic blood pressure, body mass index, hypertension, diabetes, hypercholesterolemia, smoking, exercise, alcohol consumption, parental history of myocardial infarction, treatment group, fish intake, and race/ethnicity.

Chocolate Intake and Atrial Fibrillation

Danish Diet, Cancer, and Health Study


			Cases	Person Years	Multivariable HR (95% CI)	P-Trend
All	<1/month		871	154768	1.00 (Reference)	
	1-3/month		1393	296135	0.90(0.82-0.98)	
	1/week		575	137768	0.83(0.74-0.92)	.0001
	2-6/week		442	109620	0.80(0.71-0.91)	

Higher levels of chocolate intake were associated with an 11–20% lower rate of clinically apparent AF among men and women

women	<1/month		309	83840	1.00 (Reference)	
	1-3/month		512	158627	0.94(0.82-1.09)	
	1/week		193	74173	0.79(0.66-0.95)	.017
	2-6/week		162	57185	0.86(0.71-1.05)	
	≥ 1/day		25	8783	0.84(0.55-1.27)	



Early Clinical Trials of Omega-3 Fatty Acids in Secondary Prevention of Atrial Fibrillation

Recurrent AF



Marine Omega-3 Fatty Acid and Vitamin D Supplementation and Incidence of Atrial Fibrillation

A EPA-DHA vs placebo



These findings do not support the use of marine omega-3 fatty acids or vitamin D3 in adults to prevent AF.

No. at risk	0	1	2	3	4	5	5.8
EPA-DHA	12 542	12 434	12 276	12 102	11 800	9 411	2 766
Placebo	12 577	12 476	12 328	12 165	11 858	9 456	2 765


No. at risk	0	1	2	3	4	5	5.8
Vitamin D ₃	12 553	12 449	12 290	12 131	11 828	9 435	2 759
Placebo	12 566	12 461	12 312	12 134	11 831	9 433	2 772

Mediterranean Diet and Olive Oil and AF:

The PREDIMED(Prevención con Dieta Mediterránea) Study



The Mediterranean diet with extra-virgin olive oil reduced the risk of AF(hazard ratio, 0.62; 95% CI, 0.45-0.85)



Number at risk

MeDiet+EVOO	2292	2234	2097	1798	1511	1144	496
MeDiet+Nuts	2210	2113	1899	1499	1244	903	387
Control	2203	2044	1837	1438	1152	851	358

Foundations of Cardiometabolic Health Certification Course

Certified Cardiometabolic Health Professional (CCHP)



Identification of Patients at High-Risk for AF

Usha B. Tedrow, MD MSc

Associate Professor, Harvard Medical School
Fellowship Director, Clinical Cardiac
Electrophysiology Program

Combination of Risk Factors

Atrial Fibrillation Risk Scores:
Identification of Patients at High Risk

AF Risk Prediction in Individuals without Cardiovascular Disease

Women's Health Study


<u>Base Model Covariables</u>	Beta (SE)	Adjusted HR (95% CI)	χ^2	P-Value
Ln (age)	5.475 (0.40)	238.65 (109.46-520.30)	189.6	<0.0001
Weight (per 10 kg)	0.157 (0.035)	1.17 (1.09-1.25)	20.0	<0.0001
Height (per 10 cm)	0.306 (0.082)	1.36 (1.16-1.60)	13.8	0.0002
Systolic blood pressure (per 10 mmHg)	0.155 (0.037)	1.17 (1.09-1.25)	17.7	<0.0001
2+ drinks per day	0.494 (0.20)	1.64 (1.10-2.44)	6.0	0.01
Ever smoker	0.254 (0.10)	1.29 (1.06-1.57)	6.3	0.01

C-Index = 0.75 in derivation and 0.72 in validation

CHARGE-AF Risk Score Derived in ARIC, CHS, and FHS

Final Multivariate Model for 5-year Risk of AF Derived in ARIC, CHS, and FHS


Variable
Age (5 years)
Race (white)
Height (10 cm)
Weight (15 kg)
Systolic BP (20 mm Hg)
Diastolic BP (10 mm Hg)
Smoking (current)
Antihypertensive medication
Diabetes (Yes)
Heart failure (Yes)
Myocardial infarction (Yes)
LVH by electrocardiogram (Yes)
PR Interval (<120 vs 120 to 199)
PR Interval (>199 vs 120 to 199)



- Evaluate putative novel clinical factors to reclassify an individual's risk of developing AF.
- Select high-risk individuals for trials of primary prevention or of intensive monitoring for AF detection

Variable	OR (95% CI)	OR (95% CI)
Age (5 years)	1.60	1.41 (1.24, 1.59)
Race (white)	1.46	1.27 (1.10, 1.47)
Height (10 cm)	2.48	1.97 (1.60, 2.43)
Weight (15 kg)	1.96	1.60 (1.34, 1.91)
Systolic BP (20 mm Hg)	—	—
Diastolic BP (10 mm Hg)	0.401 (0.129)	1.49 (1.16, 1.92)
Smoking (current)	0.645 (0.200)	1.91 (1.29, 2.82)
Antihypertensive medication	0.118 (0.077)	1.13 (0.97, 1.31)

Offspring AF risk by Parental h/o AF





• AF \geq 1 parent OR 1.9; (P=0.02)
 • <75yo, w/o h/o heart disease OR 3.2; (P< 0.001)

HTN	-	-	+	+	+	+
Diabetes	-	-	-	+	+	+
Heart Disease	-	-	-	-	+	+
Parent hx AF	-	+	-	-	-	+

Lifetime Risk of Developing Clinical AF

Genetic risk can stratify lifetime risk of AF



AF Genetic Risk Scores





Figure 1. Pooled 5-year relative hazard of incident atrial fibrillation (AF) among individuals in the highest quartile of AF genetic risk relative to those in the lowest quartile.

Atrial Fibrillation Genetics: Beyond Risk Prediction:



Personalized Medicine Approaches:

- AF sub-classification: Beyond Paroxysmal, Persistent, Permanent
- Outcome Prognostication
- Response to Therapy

New Targets for Therapy

Conclusions

- The reasons for the AF epidemic are not entirely clear, but partly related to aging of the population, improved longevity from CVD, improved detection, and rising obesity rates.
- There are several currently several potentially-modifiable risk factors for AF that may provide strategies for AF prevention
 - Blood pressure control
 - Weight loss
 - Moderate physical activity
 - Smoking avoidance
 - Minimization of alcohol intake.
- There are also reproductive and hormonal AF risk factors unique to women suggesting a possible impact of multiple pregnancies and estrogen on AF risk.
- Combinations of AF clinical and genetic risk factors can be utilized to identify high risk patients for targeted AF screening and future intervention trials.